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mean dose comparisons (T-pair and Kruskal-Wallis tests), log 
rank tests on event-free survivals, and probit analyses. The 
highest graded event, or in cases of similar grade the 
earliest, was considered for analyses. 
Results: One hundred and fifteen patients were eligible. Of 
them, 94.8% received concomitant chemoradiotherapy; 12.2% 
extended-field radiotherapy, and 32.2% nodal sequential 
boost. Their mean age was 47.5 years. The median follow-up 
was 35.5 months. A total of 522 events was reported. 
Focusing on the highest grade per patient: 17 had grade 0, 
75, grade 1, 20, grade 2 and 3, grade 3. The prevalence of 
grade 1 events appeared stable during the study period, 
ranging between 31.2 and 50%. The one of grade 2 events 
tended to worsen: 2.2% at 6 months, 4.5% at 1 year, 6.9% at 2 
years, and 7.0% at 3 years. Incidences of grade 2-4 events 
were 0.9% at 6 months, 6.6%, 19.0%, and 27.2% at 1, 2, 3 
years respectively. The mean D2cm3 and D0.1cm3 were 
respectively 68.7±13.6 Gy and 85.8±33.1 Gy and did not 
differ according to grade (p=0.47 and p=0.52). Comparisons 
of mean D2cm3 and D0.1cm3 according to grade 0-1 versus 2-
4 were not significant (68.0±12.4 vs 71.4±17.7 Gy, p=0.38 and 
83.7±26.4 vs 94.5±51.9 Gy, p=0.33 respectively). Log rank 
tests were performed after splitting patients into 4 groups 
according to D2cm3 levels: > 80 Gy, 70 to 79 Gy, 60 to 70 Gy 
and < 60 Gy. No difference was observed for grade 1-4 
(p=0.52), grade 2-4 (p=0.52) or grade 3-4 (p=0.21). Probit 
analyses showed no correlation between both dosimetric 
parameters and the probability of small bowel events grade 
1-4, 2-4, or 3-4 (p ranging from 0.19 to 0.48).  
 
Conclusion: No significant dose–volume effect relationships 
were demonstrated between the D2cm3 and D0.1cm3 and the 
probability of late small bowel morbidity. These two 
parameters should not limit the optimization process. 
 
OC-0352  
The high doses employed in brachytherapy of cervical 
cancer counteract hypoxia – a modelling study 
E. Lindblom
1Stockholm University, Medical Radiation Physics, Stockholm, 
Sweden 
1, A. Dasu2, I. Toma-Dasu3 
2Linköping University, Department of Radiation Physics and 
Department of Medical and Health Sciences, Linköping, 
Sweden 
3Stockholm University and Karolinska Institutet, Medical 
Radiation Physics, Stockholm, Sweden 
 
Purpose or Objective: Brachytherapy is a well-established 
radiotherapy treatment modality that has been employed in 
treatments of several cancer types for more than a century. 
One of the most common treatment strategies for cervical 
cancer today is a combination of external beam radiotherapy, 
chemotherapy and brachytherapy. Similar to other forms of 
radiation therapy, pre-treatment imaging of hypoxia is rarely 
done for cervical cancer. Nevertheless, the clinical outcome 
is highly positive, despite the fact that hypoxia has been 
repeatedly confirmed in cervical tumours. It was therefore 
the purpose of this study to investigate whether the success 
of brachytherapy in these tumours, seemingly regardless of 
oxygenation status, could be explained by the characteristics 
of the brachytherapy dose distributions in comparison to 
external beam radiotherapy. 
 
Material and Methods: A previously used in silico model of 
tumour oxygenation and radiation response was further 
developed to simulate the treatment of cervical cancer 
employing the combination of external beam radiotherapy 
and intracavitary brachytherapy. Based on the local clinical 
protocol and using a clinically derived brachytherapy dose 
distribution and assuming a homogeneous dose delivered by 
external radiotherapy, survival was assessed on voxel level 
taking into account the dose-modifying effect of the 
oxygenation as well as the effects of repair and repopulation 
of tumour cells during treatment. Two scenarios were 
considered for brachytherapy: one in which the high dose 
region was highly conformal to the hypoxic region in the 
target and one in which they were displaced relative to each 
other. Overall-response was assessed as Poisson-based 
tumour control probability (TCP). The interplay between 
tumour oxygenation and the heterogeneous high-dose 
distribution was also studied by simulating different spatial 
and temporal patterns of hypoxia. The results were compared 
to the case when irradiation was performed only with 
external beams delivering a homogeneous dose to the target. 
 
Results: Predicted values of D50 with respect to the external 
treatment and assuming reoxygenation were in agreement 
with the clinically observed high cure rates. Assuming fast 
reoxygenation, the D50 was similar for the different cases of 
overlap between the brachytherapy dose distribution and the 
tumour, regardless if the hypoxic fraction was 10% or 25% 
(Table 1). To achieve 50% control with external RT only, a 
total dose of more than 70 Gy in 25 fractions would be 
required for both cases of hypoxic fraction assuming 
reoxygenation (Figure 1). 
 
 
 
 
Conclusion: Assuming fast reoxygenation, the dependence on 
the degree and extent of hypoxia has little impact on the 
outcome and therefore the high doses delivered in 
brachytherapy could counteract the negative impact of 
hypoxia. 
 
OC-0353  
EBRT and interstitial brachytherapy for recurrent vault 
carcinomas: Factors influencing the outcomes 
R. Engineer
1Tata Memorial Centre, Surgical Oncology, Mumbai, India 
1, S. Chopra2, U. Mahantshetty2, A. Maheshwari1, 
R. Kerkar1, R. Phurailatpam2, J. Swamidas2, S.K. Shrivastava2 
2Tata Memorial Centre, Radiation Oncology, Mumbai, India 
 
Purpose or Objective: Post hysterectomy vaginal vault 
recurrences have poor outcomes with pelvic control rates 
ranging from 50-60%. We conducted this prospective study at 
our centre with an aim to determine the factors influencing 
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the outcomes of these patients treated with external beam 
radiotherapy (EBRT) and interstitial brachytherapy. 
 
Material and Methods: Ninety patients were accrued 
between October 2008 and May 2014. All the patients 
underwent prior hysterectomy and were diagnosed to have 
recurrent vault cancers with squamous cell carcinomas. Only 
patients with minimum gap of 6 months between the 
hysterectomy and recurrence were accrued in the study. All 
underwent EBRT of 50Gy (2Gy/fraction) to pelvis and 
simultaneous boost to the pelvic nodes of (10 Gy/5 fraction) 
if present, using Intensity Modulated Radiotherapy with 
concurrent chemotherapy of weekly cisplatin (40mg/mt2) 
followed by HDR Interstitial brachytherapy boost of 20Gy 
(4Gy/fraction b.i.d).  
 
Results: Eighty (88%) patients were post simple hysterectomy 
and 20(22%) had Wertheim’s hysterectomy, 16 (18%) had 
pelvic nodes and 46(51%) had parametrial extension upto the 
pelvic side walls. All the patients completed EBRT and 
concurrent chemotherapy and 28 (31%) patients had gross 
residual disease at the time of interstitial brachytherapy. 
Post brachytherapy 5 patients continued to have persistent 
disease, 6 had local relapse, 2 had local + distant relapse and 
9 patients had only distant relapse. At the median follow up 
of 42 months for the surviving patients the local control rate 
was 86% and the 5-year actuarial disease-free survival (DFS) 
and overall survival (OAS) was 75%, 71%. In univariate analysis 
OAS was influenced by tumor involving the pelvic side wall 
(55% vs 84% p=0.004) and large pelvic nodes >1cm (44% 
VS.73% P=0.01) at presentation and partial vs. complete 
tumor response to EBRT at the time of brachytherapy (40% 
vs. 83% p=0.001). On multivariate analysis pelvic nodes at 
presentation and the tumor response to EBRT were significant 
factors affecting DFS and OAS. Other factors such as age, 
disease volume, and vaginal extension did not impact the 
survivals. Grade III/IV rectal toxicity was seen in 5 (5%) 
patients, bladder toxicity in 3 (3%) patients, whereas none of 
the patients developed Grade III small bowel toxicity.  
 
Conclusion: Using EBRT with concurrent chemotherapy and 
interstitial brachytherapy a majority of the recurrences can 
be salvaged. An excellent local control and survival is 
achievable using this technique and 28 (31%) patients had 
gross residual disease at the time of interstitial 
brachytherapy.  
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Purpose or Objective: Introducing a fast technique to 
estimate bladder dose due to interfractional variations. 
 
Material and Methods: 30 cervical cancer patients treated 
with HDR intracavitary brachytherapy were selected. After 
applicator insertion all cases pelvic CT scans were performed 
twice; pre- and post-treatment (15-30 min after dose 
delivery), with applicator in situ and identical bladder filling 
protocol. A 3D treatment planning software (TPS) 
(Flexiplan®, version 2.6, Isodose control, the Netherlands) 
was used. Applicator (Rotterdam tandem-ovoid) 
reconstruction and organs contouring were done by the same 
physicist and physician on both image series. Planning was 
performed on the pre-treatment CT. Fractional prescription 
dose was calculated for each patient based on the EQD2 and 
defined planning aims: 80-90 Gy for D90 of the high-risk 
clinical target volume and D2cm³ of bladder, rectum, and 
sigmoid less than 85, 75, and 75, respectively. DVH 
parameters (D2cm³, D0.1cm³, D10, D30, and D50) were 
recorded after each planning. 192Ir dwell times were copied 
manually to the post-treatment CT in the TPS. The 
recalculations of the DVH parameters showed the 
interfractional OAR dose variations. Images and structures of 
each pre- and post-treatment plan were exported in DICOM 
format to an in-house MATLAB written code. An artificial 
neural network (ANN) based on the 'back-propagation 
algorithm' was developed to predict the OARs dose variations. 
ANN input data was based on the changes of OAR wall 
distance-to-dwell positions along the applicators, that were 
extracted from two images series of each case. 25 cases were 
randomly selected as the training and model validation set 
(20 cases for training and 5 for validation), and the last 5 one 
for the resulted ANN model testing. Testing was performed 
by comparing the interfractional dose variations obtained 
from TPS calculated DVH and that obtained from ANN-based 
computing. The performance of the ANN was analyzed by 
root mean square error (RMSE). 
 
Results: RMSE of the designed ANN was 0.28. RMSE of the 
testing cases was 0.72. TPS-based interfractional variations 
for D2cm³ were -2.9 % ± 18.7 %. As an example of the model 
performance, relative differences of TPS-calculated and ANN-
based interfractional variations for D2cm³ of the training + 
validation cases (just the first 25 ones) are presented 
schematically in the Figure 1. It can be seen that these 
relative differences are almost less than 3%. 
 
 
Conclusion: An ANN-based model was introduced which can 
give a fast prediction of bladder interfractional dose 
variations during cervical cancer intracavitary brachytherapy 
independent from TPS based dose calculations. This can serve 
as a basis for online verification tools in brachytherapy dose 
delivery. 
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Purpose or Objective: Last decade has witnessed a 
revolution in breast conservation (BCS) in India as a 
consequence of sustained awareness campaigns and 
detection of early cases. But success of BCS demands not only 
local control but cosmetic excellence as well. Radiotherapy 
plays a major role in this treatment and selected high risk 
cases require boost also . This retrospective analysis aims to 
